Supported by an educational grant from Aerie Pharmaceuticals
Upon completion of this activity, the participant should be able to:
• Discuss the chemical structure and mechanism of action of topical glaucoma medications and evolving neuroprotective medications
• Explain the anti-fibrotic activity in novel drug classes
• Evaluate novel therapeutics and classes of drugs and their potential for enhanced patient compliance
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In cooperation with Evolve Medical Education, the University of Houston College of Optometry (UHCO) has reviewed and endorsed Current and Emerging Glaucoma Therapies.
This course is COPE approved for 1.0 hour of CE credit(s) for optometrists
COPE Course ID’s: 57106-GL
COPE Activity ID: 115199
Robert D. Fechtner, MD
Professor and Chair, Department of Ophthalmology
SUNY Upstate Medical University, Syracuse, NY
Jonathan S. Myers MD
Co-Director, Glaucoma Service
Wills Eye Hospital
Robert D. Fechtner, MD has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Aerie Pharmaceuticals; Akorn Pharmaceuticals; and Novartis.
Jonathan S. Myers MD has had a financial agreement or affiliation during the past year with the following commercial interest in the form of :;Consultant: Aerie Pharmaceuticals; Allergan plc; Glaukos; MicroOptx; and Novartis AG. Speaker: Aerie Pharmaceuticals; Allergan plc; and Novartis AG. Grant Research: Aerie Pharmaceuticals; Allergan plc; Diopsys; Heidelberg Pharma; Novartis AG; Shire plc; SightSource; and Carl Zeiss Meditec.
Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education, Evolve; and Michelle Dalton, writer have no financial relationships with commercial interests. Rishi P. Singh, MD, peer reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Carl Zeiss Meditec; Genentech, Inc; Optos plc; and Regeneron Pharmaceuticals, Inc. Grant/Research Support: Apellis Pharmaceuticals; Clearside Biomedical; Genentech, Inc; Novartis AG; and Regeneron Pharmaceuticals, Inc.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, or Aerie Pharmaceuticals Inc.